{
    "Trade/Device Name(s)": [
        "LZI Buprenorphine Enzyme Immunoassay",
        "Norbuprenorphine Drugs of Abuse (DAU) Calibrators",
        "Norbuprenorphine Drugs of Abuse (DAU) Controls"
    ],
    "Submitter Information": "Lin-Zhi International, Inc.",
    "510(k) Number": "K090844",
    "Predicate Device Reference 510(k) Number(s)": [
        "K081008"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DJG",
        "DLJ",
        "LAS"
    ],
    "Summary Letter Date": "July 30, 2009",
    "Summary Letter Received Date": "June 19, 2009",
    "Submission Date": "June 18, 2009",
    "Regulation Number(s)": [
        "21CFR862.3650",
        "21CFR862.3200",
        "21CFR862.3280"
    ],
    "Regulation Name(s)": [
        "Opiate Test System",
        "Norbuprenorphine calibrators",
        "Norbuprenorphine controls"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Norbuprenorphine"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Automated clinical chemistry analyzers",
        "Hitachi 717"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme immunoassay",
        "Homogeneous enzyme immunoassay"
    ],
    "Methodologies": [
        "Enzyme immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for LZI Buprenorphine Enzyme Immunoassay, Norbuprenorphine Calibrators, and Controls for qualitative and semi-quantitative determination of norbuprenorphine in urine using automated analyzers.",
    "Indications for Use Summary": "Intended for qualitative and semi-quantitative determination of norbuprenorphine (buprenorphine metabolite) in human urine at 5 and 10 ng/mL cutoffs; calibrators and controls for use with the assay; prescription use in clinics and clinical chemistry laboratories with automated analyzers.",
    "fda_folder": "Toxicology"
}